Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039611 | 0.85 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL3037055 | 0.85 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL3029338 | 0.81 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL3035097 | 0.81 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL3041914 | 0.81 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL3034254 | 0.80 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL3044655 | 0.78 | BRAF (0.73) | BRAFRAF1 | |
| SCHEMBL5133168 | 0.76 | BRAF (0.84) | BRAFRAF1 | |
| SCHEMBL3029301 | 0.75 | BRAF (0.73) | BRAFRAF1 | |
| SCHEMBL3040951 | 0.75 | BRAF (1.00) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | claimed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.